Humanigen Inc (fka HGENQ)

[cowtown jay]

Here again, I agree with a part of what you say. The SEC gave the crooks the playground to rip off the public. But I disagree that there are no share loans. You know that can't be right, because you recognize (from somewhere - me?) that a single entity owns 110M shares. So if Humanigen controls about 90% of their OS, then management aren't the crooks, and my only question is whether Taran, or the Humanigen/Taran entity, will benefit by the forced covering, whether prompted by a merger, or by a recall of the loaned shares, or both.

I think the SEC tried to squash this situation, especially if the NIH owns so much of Moderna. If so, will this bankruptcy judge allow Humanigen's assets to be transferred to the US Treasury? Or will he order those funds to be returned to Humanigen and the injured shareholders? More often than not, judges recognize the discretionary authority of the executive branch agencies. But, in this case, the judge may recognize a conflict of interest in the agencies, and disallow the discretionary authority to convert our funds to the Treasury Department.

[DTGoody]

The Question I ask is why do this? If our shares are worthless then why is this individual so concerned about our shares? LOL

All the reason I need to stay grounded and will not sell anything.

[eb0783]

Thank god another savior decided to start another new account today and share all this unknown information.

[US-JUSTICE]

only privilleged and special accounts get to sell NAKED shares and privilleged accounts known as market makers don't have to pay fees for shorting shares either like retail accounts and can short any shares especially 'worhtless shares' at any amount of money SEC gave these crooks the playground to rip off the public.

[US-JUSTICE]

probably some 'fake' press release with fake news.
fake share buybacks there is no share buybacks you actually these guys would actually buy back shares? and there is no share loans, those naked shares that they never have to cover.

[cowtown jay]

"Currently, my primary hope is to see Cameron's leadership in action. Do you have any insights or observations in this regard?"

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173637404

Stay tuned. I think he has set the stage.

[cowtown jay]

I agree that the shares are, "... useless and worthless with the information that is available today..." and that there is a single entity, "...who still owns 110 million shares." The meaning of that entire dynamic will change with a Press Release, which I am eagerly anticipating. I think you picked a bad time to come back.

[dlraud]

That annoying busybody is back again and again.

[US-JUSTICE]

before crypto coins, tax havens like cayman islands and switzerland banks, etc were used for money laundering. and the penny stock shell companies they were used mainly for money laundering. there is no demand for tax havens in cayman island or these island as there is no privacy in all banks who has to use USD or swift banking.
anyways this ticker useless and worthless with the information that is available today. and reason the one guy who still owns 110 million shares is he controls the bankruptcy filing and needs the bankrupcy to be concluded so he can walk free from this 100 million dollar robbery. and hide the assets in some trust fund.

[US-JUSTICE]

as for now with the information that is available. the ticker hgenq is worthless and has no value and soon to be deregistered and deslisted too. it's only good as a shell company and may be dissolved and shares cancelled. good for money laundering or shell company other than no equity value.

[US-JUSTICE]

And reason the Trust is created and liquidation is so all the assets and claims of hgen is in some trust with no liens on it. so if you buy STOLEN assets from a trust, people cannot sue the trust
these people are high class theives and crooks...it's rich theives theives wearing $10,000 suits.
a theif is still a theif.
what is the point of creating a trust for and pay someone thousands per year to 'administer' it and you need to file a form to get to the assets. you trust these theives and crooks to honor anything?
there is NO HONOR among thieves.

[US-JUSTICE]

chapter 11 and chapter 7 cases are administrative process no need to waste time with 300 documents. 100% of the time equity gets zero. and shares are deregistered and company dies. A corporation has same rights as man. A dead corporation or dead man cannot repay debts. The Trust is useless. what for. the ip that Taran bought or stole for free has a LIEN on it and under common law is disputed Assets or HOT Assets or stolen assets. anyone who buys would be buying or STOLEN assets or cursed property. that is the law.

[US-JUSTICE]

this is bankruptcy fraud case and should be in criminal court not bankruptcy court.
if you feel you've been ripped don't waste time with SEC, they been paid off to ignore people who think they are ripped off.
as for the .047/share they get nothing and wasted their time probably paid $1000 bucks to apply to the 'shareholder lawsuit'
management wanted to get sued and wanted to go bankrupt so it can STEAL and buy the lenzi patent for free. okay
those FAKE creditors who want 40 million in 'disputed' should get nothing and should be countersued for harasseement with fake lawsuits but management made up the fake lawsuits. from chime an patheon.

[cowtown jay]

"... the potential of a Record Date being declared, exactly for a Distribution to shareholders (which I think could be for shares of Taran, equal to the number of our Humanigen shares)."

I don't see why a distribution to existing equity holders should not be declared. The Unsecured Creditors are looking forward to the amended plan which will increase the number and amount of payments they will receive. These Milestone Payments are based on regulatory approval which seems likely to first come from Australia as the result of our PREACH-M trial for CMML.

With the progress management has made, I truly don't see how existing equity holders could fail to be rewarded.

[cowtown jay]

I didn't try to attend the Novavax shareholders' meeting this morning, since I'm not a shareholder. So I'll have to wait 24 hours to see if relevant news was reported.

"NOVAVAX, INC.'s meeting has concluded. A replay will be available in 24 hours at: www.virtualshareholdermeeting.com/NVAX2024"

https://central.virtualshareholdermeeting.com/vsm/web?pvskey=NVAX2024

The agenda appeared pretty mundane. But they did make note of a Proxy Statement relevant to stockholders as of May 3rd.

https://novavax.widen.net/s/zdd7jdmbbj/2024-proxy-statement

So, no news from Novavax until after our Hearing today.

[cowtown jay]

DTG, the only thing that I can't figure out is why the reorganization bankruptcy was changed to a liquidating bankruptcy, but one in which a distribution may be made to existing equity holders. I can only assume that we have one too many pieces to the puzzle, and that we'll end up with shares in Taran, as the licensor of lenz to Sanofi and Novavax, and that we may merge with Novavax, and perhaps become a subsidiary of Sanofi. That would at least explain why we don't need the Humanigen shell.

Maybe, and hopefully, we'll get news tomorrow.

[DTGoody]

I hope once we see these game changing announcements come along, that they will include the CDNO stock. It would be incredible to see us brought back from the dead even though I remain skeptical. That would be Awesome!!! I am still rooting for you Jay in that you end up being right about everything.

[cowtown jay]

Leukemia patient, 17 year old Dazelle Peters, who had also suffered Acute Graft versus Host Disease, died Monday after being denied lung transplants because she was not vaccinated.

Dazelle was the embodiment of the patient populations in the RATinG and PREACH-M clinical trials sponsored by our IMPACT and SAHMRI partners. Lenzilumab may have saved the life of this beautiful young lady.

https://ir.humanigen.com/English/news/news-details/2023/Humanigen-Announces-First-Participant-Dosed-in-RATinG-Trial-of-Lenzilumab-for-Early-Treatment-of-Acute-Graft-Versus-Host-Disease-Following-Allogeneic-Stem-Cell-Transplantation/default.aspx#:~:text=(OTC%20Pink%3A%20HGEN)%2C,clinical%20trial%20network%20delivering%20innovative

https://ir.humanigen.com/English/news/news-details/2022/Humanigen-and-SAHMRI-Announce-Expansion-of-the-PREACH-M-Study-of-Lenzilumab-in-CMML/default.aspx

[cowtown jay]

As JFK said, a rising tide lifts all boats. This might explain an increased interest in Humanigen.

As Zack's Equity Research noted, "Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks Equity Research
Mon, Jun 10, 2024...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately...Shares of this vaccine maker have returned +104.6% over the past month versus the Zacks S&P 500 composite's +3.3% change...For the current quarter, Novavax is expected to post earnings of $1.13 per share, indicating a change of +94.8% from the year-ago quarter. The Zacks Consensus Estimate has changed +241.6% over the last 30 days...The consensus earnings estimate of $0.37 for the current fiscal year indicates a year-over-year change of +106.8%. This estimate has changed +144.5% over the last 30 days."

https://finance.yahoo.com/news/investors-heavily-search-novavax-inc-130016966.html

Novavax further provides FLS cautions as follows. "... (Our) and Sanofi’s ability to successfully implement its partnership, including the ability to transition key processes and effect technology transfers, Novavax’s and Sanofi’s ability to successfully develop or commercialize any vaccines or vaccine candidates, our ability to successfully and timely manufacture, distribute, or market our updated COVID-19 vaccine including as a single dose vial or pre-filled product presentation for the 2024-2025 vaccination season, our plans to sell our COVID-19 vaccine for the 2024-2025 vaccination season under Emergency Use Authorization; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials; challenges or delays in obtaining regulatory authorization for our product candidates, including our updated COVID-19 vaccine in time for the 2024-2025 vaccination season in the U.S. and in foreign jurisdictions to meet APA commitments or for future COVID-19 variant strain changes, our COVID-19-Influenza combination vaccine candidate and our stand-alone influenza vaccine candidate; manufacturing, distribution or export delays or challenges; our substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling and PCI Pharma Services for finishing our COVID-19 vaccine and the impact of any delays or disruptions in their operations on the delivery of customer orders..."

https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000110465924068875/tm2416490d1_8k.htm

I didn't know that Novavax had a business relationship with PCI Pharma, but I knew of Humanigen's relationship with PCI. I also see Cenexi being mentioned in other posts, and I know we also had a business relationship with them. The closer we get to Novavax's stockholder meeting tomorrow, which is also when we will hear about the bankruptcy court's decision regarding our expanded and increased Asset Purchase Agreement, and a possible distribution to existing equity holders of Humanigen shares, the more optimistic I become.

[cowtown jay]

I hope to see two game-changing announcements from Humanigen this week, or in the near term. One announcement may be in regards to further utilizing our notice of patent allowance for the enhancement of CAR-T immunotherapy.

https://www.pennystockdream.com/blog/hgen-up-3217-after-hours-after-receiving-notice-of-allowance-for-patent-application

I actually think that Gracell and Mayo Clinic are already benefitting from this CAR-T enhancement, and I hope that Sanofi will bring this to market not only for their platforms, but for our partner, the South Australian Health and Medical Research Institute ("SAHMRI"), also.

""Expansion of the PREACH-M study is a critical next step in our realignment strategy. Associate Professor Thomas is a world expert in CMML and program leader for Blood Cancers at SAHMRI. SAHMRI is a leader in precision medicine that assists patients in finding the proper treatment for their cancer," commented Cameron Durrant, Chairman and CEO of Humanigen. "Lenzilumab was discovered in Australia, so it is only fitting that we leverage the wealth of local knowledge that exists for lenzilumab as we continue clinical development."

https://ir.humanigen.com/English/news/news-details/2022/Humanigen-and-SAHMRI-Announce-Expansion-of-the-PREACH-M-Study-of-Lenzilumab-in-CMML/default.aspx

The second announcement I'm looking forward to will be after the Novavax stockholder meeting on the 13th, which coincides with our bankruptcy hearing detailing the expanded Milestone Event triggers and payments.

[cowtown jay]

Chris Cuomo interviews Dr. Robert Redfield on the many ways Long Covid presents. The gist of the discussion is summarized in the last 8 minutes of the video. I share this video because I think we are only beginning to understand just how much we really don't understand, if that makes sense to you. This lack of understanding frustrates me to no end. The frustration started in 2020 as my wife's condition deteriorated, and there was no no appreciation of how lenz could improve her brain functioning. And the frustration continues as I look at the swelling in my right foot and calf, despite taking an anti-coagulant and blood thinner, which I think lenz could improve by reducing the inflammation.

Man, I'm looking forward to getting lenz into the hands of the medical community, where the real discovery can begin.

[cowtown jay]

Yes, Humanigen is still around, and there is a bankruptcy court Hearing scheduled in 3 days, on the 13th, in this matter,

see page 3, para 7
https://reorgdocumentlibrary.broadridge.com/Client/Client?data=0524/N03355/444863/c

A few of my recent posts on this subject reflect my optimism and have had hundreds of views accumulated on the X platform. Perhaps this is the result of Michael North communicating with prospective Humanigen/Taran investors. After all, there are significant movements of Sanofi and Novavax, and I suspect we will figure into the evolving structures of these companies.

[pipette]

Is HGEN still around? Didn't they go bankrupt? I am behind in my news.

[cowtown jay]

"And there are a host of other indications, including asthma, arthritis, malaria, Long Covid, etc., that I think will far surpass anyone's expectations."

"Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
By Michael Erman
June 7, 2024

June 7 (Reuters) - A 15-day course of Pfizer's (PFE.N), opens new tab COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.

Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection."

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-paxlovid-fails-15-day-treatment-long-covid-study-finds-2024-06-07/#:~:text=June%207%20(Reuters)%20%2D%20A,study%20by%20Stanford%20University%20researchers.

[cowtown jay]

Yes, in part, and as I have previously made clear, some of my conclusions, particularly in regards to Novavax, have no basis in fact, and simply reflect a blaringly obvious solution to the unmet needs of both Humanigen and Novavax, as only they can meet for each other with such a high degree of success. I am highly confident in what Dubovsky can contribute toward our international approval and usage of lenz.

My pinned post, which reflects the last communication from Humanigen, focuses on our opportunities as otherwise noted in my post. And I think Sanofi will enable our ability to penetrate the market beyond covid and into oncology and hematology.

I have read and studied the material on Humanigen over the years, just as I read and studied my college textbooks. No relevant communication with management, other than that, except for conveying my appreciation of management, as I am doing now, because I think they are entirely worthy of shareholder support. Hopefully, we'll all have the financial reward they have worked to provide for us, and many more shareholders will share my appreciation of them after that gain is realized.

[dloggold]

you realize there is no evidence for your claims , it's completely made up in your head yes? thats unless you have information that nobody else has, trying to contact these guys is like trying to find an outhouse in Antarctica so i highly doubt you have spoken to anyone.

[dloggold]

i guess vaccine shaming has been forgotten and forgiven.
john nash would be proud

[cowtown jay]

Diego, I think management may have secured a revenue stream through licensing fees from Gracell, Mayo Clinic, Novavax, Sanofi, our PREACH-M and aGvHD partners. and others TBA, that will pay the $44M to our unsecured creditors, and negate the reason to remain in bankruptcy. How management wants to capitalize on the recall of their loaned shares remains to be seen and is irrelevant to me. And there are a host of other indications, including asthma, arthritis, malaria, Long Covid, etc., that I think will far surpass anyone's expectations. The Do or Die bankruptcy hearing is scheduled next week, on the 13th. If I have overstated our potential, it's because you sincerely asked if I thought there was something that could move the stock price. But even a more limited version of our opportunities could prove sufficient to successfully exit our CH11 proceeding.

It just makes no sense to raise the subject of an expanded program to meet Milestone Events without Humanigen capitalizing on their share structure and offering some type of distribution to existing equity holders, chiefly the company.

[Diego Rivas]

What do you mean with our last week in purgatory? You mean something could move the stock price?

[cowtown jay]

You're a good man, eb, and I appreciate your continued support. But the amended Asset Purchase Agreement was probably the best news we could have received. I look forward to hearing from Michael North on how Taran and Humanigen may be integrated, and I suspect that Filip Dubovsky may have a key role in the expansion of our Milestone Events, which I think will shock the investment community...and the short sellers who have bet against us. Also, I credited Dubovsky for a possible role in the Pfizer covid trial, but Michael Shuster is who I should have credited. I hope this is our last week in purgatory.

[eb0783]

Hang in there Jay. You have been through it before and I'm sure no one here understands what you see here. Keep it going; I love your determination.

[dloggold]

nothing is happening

[cowtown jay]

As I indicated in the link I provided, the date for the Combined Hearing is June 13th.

I'm fully aware of the warning that existing shareholders may not receive a distribution from the Liquidating Trustee.

But I am convinced that the co-exclusive licenses held by Sanofi and Novavax, will prove to be a game-changer for Humanigen shareholders. I actually think Novavax has received funds they can use to pay their licensing fee to Taran, which could fully satisfy the Unsecured Creditors, and that Taran will possibly offer an exchange of equities to Humanigen shareholders.

There is just not enough information for me to speculate on whether Sanofi will also provide licensing fees to Taran, and how Humanigen shares may be converted to Taran shares, nor how to tell what the outcome will be of a possible combination of Sanofi, Novavax, Humanigen, and Taran.

But, in light of the warning about potentially no distribution to Humanigen shareholders, coupled with my commitment to have a reasonable basis for my conclusions, I am saying that I expect a successful conclusion to our CH11.

[All-Bidness]

What meeting on June 13th? No notice went out. Company is done

[cowtown jay]

Novavax just hit another new 52 week high of $22.24 today.

[Diego Rivas]

Can someone make me a summary of what is going on and what could happen with $HGEN?

[cowtown jay]

Novavax just eliminated the possibility of recipients topping-out on awards granted to them under their 2015 Stock Plan. This will positively impact Dubovsky, who I think we'll see named as our Chief of Development. Their June 13th Stockholders Meeting coincides with our June 13th Combined Hearing.

"AMENDMENT TO PROXY STATEMENT DATED APRIL 29, 2024, FOR THE NOVAVAX, INC. 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 13, 2024."

https://www.sec.gov/Archives/edgar/data/1000694/000110465924068426/tm2416428d1_defa14a.htm

See pg 3, The Combined Hearing

https://reorgdocumentlibrary.broadridge.com/Client/Client?data=0524/N03355/444863/c

[cowtown jay]

Well, Novavax did end up making a 52 week high yesterday. I'm hopeful that they will be using lenz as a vaccine enhancement, and that we see them make an all-time high, which would be over $300 per share, and maybe result in filling my open sell orders at $200 before the orders expire early in July.

[cowtown jay]

"... it was the Combined Plan and Disclosure Statement that vested sole discretion into the Liquidating Trustee to declare a Record Date for a Distribution to Existing Equity Holders."

As I recall, it is the SEC that proposes which Bankruptcy Trustee they want. In my previous experience, the Trustee and the bankruptcy judge discussed the rampant naked shorting of the victimized company that was forced into bankruptcy, and decided not to accumulate a required list of the victimized shareholders, just due to the excessive scope of the problem. Subsequently, the SEC entered into a Settlement Agreement with the Bankruptcy Trustee to deregister the shares, which required the judge's approval.

We obtained the required list of NOBO/OBO shareholders by subpoena. We also argued against the Settlement Agreement, and the judge denied that Agreement.

My point is that Bankruptcy Trustees have a vested interest in accommodating the SEC, by whom they are recommended as Trustees. I think that presents a conflict of interest, and the Trustees should be nominated by a disinterested party (the Consumer Financial Protection Agency, for example). A second point is that shareholders have significant power that can be granted to them by the judge.

I've been reticent speak too much since Liquidation was declared, and that guidance was provided to advise shareholders that no distribution to them was anticipated.

However, it is evident that Humanigen's circumstances have changed (or are changing), to the point where I expect that a distribution will be made to existing equity holders. We see support in that regard by the amended Asset Purchase Agreement, which will significantly expand the Milestone Events, and payments to the Unsecured Creditors.

We see Dubovsky altering his career path from Novavax's President of R&D, as we see Sanofi begin their spin-off, at the same time that we see both companies acknowledge their co-exclusive licensing agreement, which I suspect will be for lenz. I think it is these changes that will ignite the significantly expanded Milestone Events, and will also trigger Humanigen's recall of their loaned shares.

[cowtown jay]

I see Gilead trading near 52 week lows today, while Novavax is trading near 52 week highs.

I suspect this illustrates why management did not want to give Gilead exclusive rights to use lenz. Rather, if I'm right, we'll see that lenz is the product co-exclusively licensed to Sanofi and Novavax. And hopefully, Dubovsky has helped to demonstrate that lenz improves the efficacy of azacitidine in treating, or preventing, Myelodysplastic cancers, perhaps significantly beyond what he and Pfizer demonstrated in their trials.

Of course, we know that Gilead gave up on their effort in this regard, after spending almost $5B to buy magrolimab, which failed to show improved efficacy, and in fact, resulted in increased mortality.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174481489

[cowtown jay]

If North knows what he is getting into by establishing communications with investors and key shareholders of Humanigen's stalking horse bid winner, then he must know about Taran's strategy going forward, and believe that there is sufficient value to warrant the investment he will be soliciting.

And, since our bankruptcy judge has kept us in a CH11 proceeding, he should be equally informed about Humanigen's prospects and strategy as it relates to shareholder value.

Existing equity holders were excluded from voting on the Combined Plan and Disclosure Statement. However, it was the Combined Plan and Disclosure Statement that vested sole discretion into the Liquidating Trustee to declare a Record Date for a Distribution to Existing Equity Holders. The Declaration of a Record Date would not adversely affect the superior claim holders in any way. In fact, it could add value to their claims, if certain Causes of Action are implemented.

Existing equity holders should be permitted to Object to an arbitrary denial of our Preservation of Rights. I see no reason why the judge, rather than the Liquidating Trustee, should not retain the authority to Declare a Record Date, if requested by the Debtor.

[cowtown jay]

There may be something we could learn from Sanofi's acquisition of Inhibrx, Inc. I see some similarities in the set-up of the acquisition. It's beyond my pay grade.

https://www.sec.gov/Archives/edgar/data/1121404/000119312524150383/d843856dex991.htm

[sosjtb]

“in which they note a Deagel study which projects the US population to decline by as much as 200M by 2025. “

That’s 2/3rds of the US population in the next 6 months, I’m guessing that was written wrong?

[cowtown jay]

Hello, D

First of all, let me say that I appreciate your continued consideration of my posts. The issue of how the bankruptcy concludes, in my opinion, should now consider whether Humanigen still meets bankruptcy parameters, especially in regards to liquidation. I don't think they do. I think we should see our status changed from liquidation, back to reorganization, from which we should emerge with our share structure intact.

Something else I have long believed is that we are engaged in biowarfare. I view the illegal mass migration of non-Europeans into the US in support of that claim. That claim is also reinforced by the tens of thousands of Chinese nationals who have entered our country illegally. These immigrants are not susceptible to the covid strains designed based on national DNA databases. A good discussion of this topic is based on an interview by Matthew Smith of Doug Casey, in which they note a Deagel study which projects the US population to decline by as much as 200M by 2025.

I use the two above paragraphs to illustrate how lenz is the premier therapeutic THAT WILL BE REQUIRED to face this onslaught. I would rather posit the scenario, even if too extreme, because it is entirely appropriate to have countermeasures in place for such contingencies.

[cowtown jay]

"Research into Disease X also requires gain-of-function utilization, to possibly produce another novel coronavirus, which I think could be the Pangolin Coronavirus GX_P2V..."

More recent discussion suggests that "Disease X" could actually prove to be a version of H5N1 bird flu, which could be, or will become, genetically modified. Dr. Kelly Victory, one of my favorites, conducted an excellent interview of Dr. Brian Hooker, PhD, on this subject of "H5N1 Bird Flu: New Pandemic Gets New mRNA Vaccine," starting at minute marker 09:30 in the following video.

However, I don't think this is necessarily going to be a lather-rinse-repeat of what we have seen in the programmed governmental response to covid.

I'm glad to see that Sanofi acknowledged their co-exclusive licensing agreement with Novavax yesterday.

https://www.sec.gov/Archives/edgar/data/1121404/000119312524147826/d839421d6k.htm

I was hoping that we would finally hear from Humanigen/Taran that lenz is the product being licensed to Sanofi and Novavax for their covid and covid/flu vaccines. For that matter, I'd like to see that Gracell and Mayo Clinic may also announce co-exclusive licensing of lenz for their CAR-T platforms.

The point is, that while regulators will likely continue to push for mRNA vaccines for their sponsors' covid/flu products, trials are underway for Novavax/Sanofi to use traditional vaccine technology, hopefully enhanced by lenz.

Billions of covid revenue dollars are at stake for Humanigen/Taran, along with Sanofi and Novavax. I think management has captured that opportunity for us. I think we should know by the 13th, perhaps earlier if the Liquidating Trust is dissolved.

[cowtown jay]

It begs the question, since Humanigen has no secured debt obligations; no non-tax priority claims; and the unsecured creditors are voting to approve the amended APA in anticipation of a rigorous response toward accomplishing Milestone Events, then why shouldn't the CH11 bankruptcy be discharged with the share structure absorbed, as the company emerges from this reorganization?

An old skeptical challenge to such a Phoenix re-emergence of life, would be to ask, "How did this happen? Did the company discover a cure for cancer or something?" And the answer is likely yes, for cancers such as CMML.

[InfinitePhoenix4]

That’s interesting.

[cowtown jay]

It could be the butterfly effect. But my long-standing, pro-bias toward Novavax has me convinced that they and Humanigen have such mutual benefit by partnering, that Filip may very well slip into a Chief position with the Taran/Humanigen entity.

But I'm even more excited about the amended Asset Purchase Agreement, where it was indicated that, "...The settlement amended the APA to, among other things, significantly expand the events that will trigger the contingent “Milestone Payments” and increase the amount of those payments under the APA."

end of 2nd para, pg 4/5
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1075977&projectCode=HUM&docketNumber=235&source=DM

About two weeks later, we got a little mixed messaging in Doc 253, where it was noted that no distribution to shareholders was anticipated, but that same paragraph concluded with the potential of a Record Date being declared, exactly for a Distribution to shareholders (which I think could be for shares of Taran, equal to the number of our Humanigen shares).

see 1st para, pg 3
https://reorgdocumentlibrary.broadridge.com/Client/Client?data=0524/N03355/444863/c

[InfinitePhoenix4]

Yeah it’s the butterfly effect .

[cowtown jay]

Is Filip Dubovsky retiring as Novavax's President of R&D, after recent patent grants, including some that were Granted in February and March, 2024?

https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000110465924064680/tm2415419d1_8k.htm

https://patents.justia.com/assignee/novavax-inc

Will he be joining in the Sanofi spin-off company, perhaps merged with the Humanigen/Taran entity, and Novavax?